William Henning, DO
Neurology · Great Falls, MTNPI 1053495432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,047 and has fallen 58.1% since, to $439 in 2025.
Across 232 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$476
- Teva Pharmaceuticals USA, Inc.$453
- Biogen$415
- Sanofi$364
- Amgen$264
- Genentech USA, Inc.$185
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$782%
- Food & beverage$3,58194%
- Education$1594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $476 |
| Teva Pharmaceuticals USA, Inc. | 25 | $453 |
| Biogen | 41 | $415 |
| Sanofi | 23 | $364 |
| Amgen(2 entities) | 11 | $264 |
| Genentech USA, Inc. | 13 | $185 |
| Bristol Myers Squibb | 11 | $178 |
| AbbVie | 7 | $165 |
| AstraZeneca | 9 | $161 |
| Argenx US, Inc. | 4 | $146 |
| Neurocrine Biosciences, Inc. | 7 | $124 |
| Sarepta Therapeutics, Inc. | 5 | $105 |
| EMD Serono, Inc. | 7 | $96 |
| Acorda Therapeutics, Inc | 5 | $78 |
| TG Therapeutics, Inc. | 3 | $76 |
| Sunovion Pharmaceuticals Inc. | 6 | $74 |
| Lilly USA, LLC | 3 | $56 |
| UCB, Inc. | 3 | $52 |
| Genentech, Inc. | 1 | $48 |
| Johnson & Johnson | 2 | $42 |
| Eisai Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Tanabe Pharma America, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Neurelis, Inc. | 1 | $19 |
| CSL Behring | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$100
How this compares
$3,819 in reported general payments places this provider in the 70th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 14 | $144,329 |
| IngrezzaValbenazine Tosylate | 12 | $100,568 |
| NuplazidPimavanserin Tartrate | 14 | $69,965 |
| OngentysOpicapone | 14 | $9,064 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 69 | $2,606 |
| Ropinirole Hcl | 86 | $2,345 |
| Donepezil Hcl | 37 | $1,452 |
| Pyridostigmine Bromide | 18 | $1,330 |
| AmantadineAmantadine Hcl | 17 | $1,109 |
| Primidone | 43 | $987 |
| Mycophenolate Mofetil | 12 | $919 |
| Gabapentin | 16 | $553 |
| Pregabalin | 17 | $428 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $301 |
| Memantine Hcl | 17 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $96 | $144,32914 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $124 | $109,63126 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $12 | $2,24930 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $27725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 neurology providers in Montana.
Other neurology in Great Falls
- Dennis DietrichGreat Falls$140K
- Deborah DoverGreat Falls$19K
- Eliad CulceaGreat Falls$19K
- Walter Lajara-NansonGreat Falls$6K
- Cody SandersGreat Falls$1K
- Ann CollierBillings$164K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
- Norman FriedmanKalispell$35K
- Emily PharrBozeman$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.